A body of such molecular, preclinical, and clinical evidence of interest to chordoma oncogenesis has begun to emerge for several kinases: Epidermal Growth Factor Receptor (EGFR), Cyclin-dependent kinase 4 (CDK4), Cyclin-dependent kinase 6 (CDK6) and the mammalian target of rapamycin (mTOR). The gene discussed is EGFR; the disease is chordoma.